HSA
SNOA icon

Hussman Strategic Advisors’s Sonoma Pharmaceuticals SNOA Stock Holding History

Hussman Strategic Advisors’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-155
Closed -$23K – 351
2021
Q2 		$23K Buy
+155
New +$24.3K ﹤0.01% 334

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Hussman Strategic Advisors's SNOA Position: Q3 2021 in Review

Hussman Strategic Advisors sold out of Sonoma Pharmaceuticals (SNOA) in Q3 2021, closing a stake of 155 shares — an estimated $23K sold.

Hussman Strategic Advisors first reported a position in SNOA in Q2 2021 and held it in 1 quarter. The position peaked at $23K in Q2 2021. 20 funds tracked by Wall St. Rank hold SNOA as of Q3 2021.

  • Hussman Strategic Advisors reported no remaining Sonoma Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Hussman Strategic Advisors sold 155 Sonoma Pharmaceuticals shares in Q3 2021, an estimated $23K.
  • Hussman Strategic Advisors first reported a position in Sonoma Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Hussman Strategic Advisors's Sonoma Pharmaceuticals position peaked at $23K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q3 2021.

Based on Hussman Strategic Advisors's 13F filing for Q3 2021, filed 1 Nov 2021.